Heart Views (Jan 2020)

Brugada syndrome: Clinical features, risk stratification, and management

  • Balal Rasheed Malik,
  • Ahmed Mohamed Ali Rudwan,
  • Mohamed Salah Abdelghani,
  • Mohammed Mohsen,
  • Shahul Hameed A. Khan,
  • Nora Aljefairi,
  • Elsayed Mahmoud,
  • Nidal Asaad,
  • Sajad Ahmed Hayat

DOI
https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_44_20
Journal volume & issue
Vol. 21, no. 2
pp. 88 – 96

Abstract

Read online

In 1992, the Brugada brothers published a patient series of aborted sudden death, who were successfully resuscitated from ventricular fibrillation (VF). These patients had a characteristic coved ST-segment elevation in the right precordial leads on their 12-lead electrocardiogram with no apparent structural heart abnormality. This disease was referred to as “right bundle branch block, persistent ST-segment elevation, and sudden death syndrome.” The term Brugada syndrome (BrS) was first coined for this new arrhythmogenic entity in 1996. BrS is more prevalent in Southeast Asian ethnic groups and was considered a familial disease due to the presence of syncope and/or sudden deaths in several members of the same family, however, the genetic alteration was only noted in 1998. The genetic characterization of BrS has proven to be challenging. The most common and well-established BrS genotype involves loss-of-function mutations in the SCN5A gene, but only represents between 15% and 30% of the diagnosed patients. Patients with BrS can present with a range of symptoms which can include syncope, seizures, and nocturnal agonal breathing due to polymorphic ventricular tachycardia or VF. If these arrhythmias are sustained, sudden cardiac death may result. Despite the significant progress on the understanding of BrS over the last two decades, there remain a number of uncertainties and challenges; we present an update review on the subject.

Keywords